Br J Cancer: Down-regulation of ITGA6 expression enhances the invasiveness of multiple myeloma and promotes its development into plasma cell leukemia

Multiple myeloma (MM) is a bone marrow-based malignant tumor characterized by the proliferation of clonal plasma cells.
During the development of MM, cancer cells have the ability to proliferate in areas other than the bone marrow, manifesting as plasma cell leukemia.

Multiple myeloma (MM) is a bone marrow-based malignant tumor characterized by the proliferation of clonal plasma cells.
Multiple myeloma (MM) is a bone marrow-based malignant tumor characterized by the proliferation of clonal plasma cells.

According to the source, plasma cell leukemia can be divided into two types: one is newly diagnosed primary plasma cell leukemia (pPCL), and the other is secondary plasma cell leukemia (sPCL) that appears in recurrent MM .

According to the source, plasma cell leukemia can be divided into two types: one is newly diagnosed primary plasma cell leukemia (pPCL), and the other is secondary plasma cell leukemia (sPCL) that appears in recurrent MM .
According to the source, plasma cell leukemia can be divided into two types: one is newly diagnosed primary plasma cell leukemia (pPCL), and the other is secondary plasma cell leukemia (sPCL) that appears in recurrent MM .
diagnosis

sPCL is an aggressive form of MM, but the relevant mechanism for the development of MM into PCL is still unclear.

The study analyzed the gene expression profiles of MM patients and PCL patients to identify molecular differences between the two diseases.
Through Cox survival curve and Kaplan-Meier analysis, the impact of ITGA6 (integrin subunit α6) on the prognosis of MM patients was evaluated.

The invasion assay can be used to assess whether ITGA6 regulates the development of MM to PCL.

ITGA6 may regulate the development of MM to PCL

The results showed that gene expression profile analysis showed that the cell transfer pathway was enriched in PCL patients, and the differential expression of ITGA6 was found in PCL and MM patients.
The researchers found that the expression level of ITGA6 is an independent prognostic factor of event-free survival (EFS) and overall survival (OS) in MM patients.

The expression level of ITGA6 is an independent prognostic factor of event-free survival (EFS) and overall survival (OS) of MM patients.
The expression level of ITGA6 is an independent prognostic factor of event-free survival (EFS) and overall survival (OS) of MM patients.

The current prognostic indicator of MM is the International Staging System (ISS).
Researchers have found that when ITGA6 is expressed, the ability of MM to stratify ISS is improved.

Functional studies have shown that the increase of ITGA6 can reduce the invasion of myeloma cells.

ITGA6 mediates the invasion of MM cells

All in all, the results of this study show that during the malignant progression of plasma cells, the level of ITGA6 gradually decreases, and the low expression of ITGA6 contributes to the metastasis of myeloma.
In addition, the expression level of ITGA6 helps to analyze the prognostic stratification of MM patients.

The results of the study showed that during the malignant progression of plasma cells, the level of ITGA6 gradually decreased, and the low expression of ITGA6 contributed to the metastasis of myeloma.
The results of the study showed that during the malignant progression of plasma cells, the level of ITGA6 gradually decreased, and the low expression of ITGA6 contributed to the metastasis of myeloma.

Original source:

Song, S.
, Zhang, J.
, Su, Q.

et al.
org/10.

org/10.

Leave a message here